Tools   Select Another Resource Report Type

http://www.parkinsoninfo.org

THIS RESOURCE IS NO LONGER IN SERVICE, documented on May 18th, 2016. A foundation that was founded in 2001, and sponsors academic centers throughout the US. The MIchael Stern Parkinson's Research Foundation focuses its efforts mainly on finding the causes of the disease, finding effective treatments, and discovering a cure for the disease. The foundation is notably looking into dopamine and its effects on neural connections, as well its possibility to be used for treatment.
Dr. Greengard has assembled a close knit group of more than 25 outstanding scientists who are focused on translating the fundamental understandings about the dopamine system into new treatments for Parkinson's. The core team of researchers is based at the Stern Foundation laboratory on the campus of The Rockefeller University interacts continually with collaborators from the United Kingdom, France, Sweden, Italy, Japan and Korea. This global presence ensures that no promising research lead is overlooked, and that progress can be made on multiple fronts simultaneously. As the Foundation grew it was able to expand its support for critical neurological research to two other institutions, Harvard University's McLean Hospital, where we support the research of Dr. Ole Isacson whose research lab, The Stern Center for Neuroregeneration Research is using gene therapy to protect the most vulnerable neurons in PD models; and the Institute for Neurodegenerative Disorders, where Yale Professors Dr. Ken Marek and Dr. John Seibyl are developing novel tools for early detection and monitoring of Parkinson's disease by studying physiologic, biochemical and neuroimaging biomarkers for non-dominergic manifestations of Parkinsonism. :NIF thanks the Parkinson's Disease Foundation, http://www.pdf.org for their referral of this resource to us.

Proper citation: Michael Stern Parkinsons Research Foundation (RRID:SCR_008098) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/TMO

A high level patient-centric ontology for the pharmaceutical industry. The ontology should enable silos in discovery research, hypothesis management, experimental studies, compounds, formulation, drug development, market size, competitive data, population data, etc. to be brought together. This would enable scientists to answer new questions, and to answer existing scientific questions more quickly. This will help pharmaceutical companies to model patient-centric information, which is essential for the tailoring of drugs, and for early detection of compounds that may have sub-optimal safety profiles. The ontology should link to existing publicly available domain ontologies.

Proper citation: Translational Medicine Ontology (RRID:SCR_010439) Copy   

•   Source: SciCrunch Registry

http://purl.bioontology.org/ontology/BP-METADATA

Ontology that represents the structure that BioPortal uses to represent all of its metadata (ontology details, mappings, notes, reviews, views)

Proper citation: BioPortal Metadata Ontology (RRID:SCR_010167) Copy   

•   Source: SciCrunch Registry

http://www.nimh.nih.gov/funding/clinical-trials-for-researchers/practical/step-bd/index.shtml

A long-term outpatient study designed to find out which treatments, or combinations of treatments, are most effective for treating episodes of depression and mania and for preventing recurrent episodes in people with bipolar disorder. This study has been completed. (2005) STEP-BD is evaluating all the best-practice treatment options used for bipolar disorder: mood-stabilizing medications, antidepressants, atypical antipsychotics, and psychosocial interventions - or talk therapies - including Cognitive Behavioral Therapy, Family-focused Therapy, Interpersonal and Social Rhythm Therapy, and Collaborative Care (psychoeducation). There are two kinds of treatment pathways in STEP-BD, and participants may have the opportunity to take part in both. The medications and psychosocial interventions provided in these pathways are considered among the best choices of treatment for bipolar disorder in everyday clinical practice. In the Best Practice Pathway, participants are followed by a STEP-BD certified doctor and all treatment choices are individualized. Everyone enrolled in STEP-BD may participate in this pathway. Participants and their doctors work together to decide on the best treatment plans and to change these plans if needed. Also, anyone who wishes to stay on his or her current treatment upon entering STEP-BD may do so in this pathway. Adolescents and adults age 15 years and older may participate in the Best Practice Pathway. For adults age 18 and older, another way to participate is in the STEP-BD Randomized Care Pathways. Depending on their symptoms, participants may be offered treatment in one or more of these pathways during the course of the study. The participants remain on mood-stabilizing medication. However, because doctors are uncertain which of several treatment strategies work best for bipolar disorder, another medication and/or talk therapy may be added. Each Randomized Care Pathway involves a different set of these additional treatments. Unlike in the Best Practice Pathway, the participants in the Randomized Care Pathways are randomly assigned to treatments. Also, in some cases, neither the participant nor the doctor will be told which of the different medications is being added. This is called a double-blind study and is done so that the medication effects can be evaluated objectively, without any unintended bias that may come from knowing what has been assigned. Participants will not be assigned medications that they have had bad reactions to in the past, that they are strongly opposed to, or that the doctor feels are unsuitable for them. The medication(s) participants may be randomly assigned to in the Randomized Care Pathways are free of charge. There are other treatment options for participants if they do not respond well to the treatment assigned to them. Also, participants may return to the Best Practice Pathway at any time. About 1,500 individuals will be enrolled in at least one Randomized Care Pathway during their period of participation in STEP-BD. It is important to note that STEP-BD provides continuity of care. For example, if a participant starts out in the Best Practice Pathway and later chooses to enter one of the Randomized Care Pathways, he or she continues with the same STEP-BD doctor and treatment team. Then, after completing the Randomized Care Pathway, the participant may return to the Best Practice Pathway for ongoing, individually-tailored treatment. Follow the link to view study info at Clinicaltrials.gov, http://www.clinicaltrials.gov/ct/show/NCT00012558?order=1

Proper citation: Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) (RRID:SCR_008844) Copy   

•   Source: SciCrunch Registry

http://www.neurosci.umn.edu/

The graduate program in neuroscience at the University of Minnesota is a large, multidisciplinary program consisting of over 100 faculty members from all parts of the University of Minnesota, over 25 departments from over 10 colleges. The multidisciplinary nature of the Ph.D. program is one of its most significant strengths.

Proper citation: University of Minnesota Graduate Program in Neuroscience (RRID:SCR_007516) Copy   

•   Source: SciCrunch Registry

http://www.topqbiosystems.com

Contract research organization that performs IHC detection of antigens in tissue and cell samples. Some target antigens are difficult-to-detect because of various reasons. We offer the following quality IHC services with the primary antibodies provided by customers: -Primary antibody selections -Formalin fixed paraffin embedded (FFPE) tissue sample sectioning -Processing condition optimizations -IHC single or double staining (colorimetric or fluorescent) FFPE slides TMA slides -IHC data analysis

Proper citation: TopQ BioSystems (RRID:SCR_012424) Copy   

•   Source: SciCrunch Registry

http://www.scienceexchange.com/facilities/enzymatics

Enzymatics is an independent, ISO 13485:2003 certified OEM manufacturer of enzymes that brings to the marketplace a unique, quality oriented, and customer focused approach to protein production. The company was founded in 2006 to specifically address the needs of commercial entities engaged in the development, manufacture, and distribution of platforms dedicated to nucleic acid identification. Enzymes are critical to the performance of these applications and the industry''s relentless pursuit of higher performance emphasizes the need for analytical reagent purity and absolute production consistency. Operating from the perspective that we are a manufacturing division of our customer, Enzymatics consistently delivers the highest quality and value enzymes, leveraging them to drive customer success via a partnership business model; and our tremendous success confirms the need in the marketplace for a dedicated partner in the realm of enzyme technologies.

Proper citation: Enzymatics (RRID:SCR_012545) Copy   

•   Source: SciCrunch Registry

http://www.cerep.fr/Cerep/Users/pages/ProductsServices/InVitro.asp

Cerep offers a panel of over 630 validated in vitro pharmacological assays that cover a broad range of targets including receptors, ion channels, transporters, enzymes and second messengers. These assays are used to identify lead compounds, to define mechanism of action, and to identify off-target activities. All assays are available on an ad hoc basis. At any time, clients can select one or more assays to be tested against one or more compounds at one or more concentrations. In addition to ad hoc access, client specific and Cerep profiles are available. Client specific profiles can be adapted using any of the over 630 Cerep assays. Standard Profiles are designed by Cerep and available to all clients. The Standard Profiles are a rapid and cost effective way of prioritizing the most promising compounds in the lead selection process. Benefiting from increased efficiency generated from optimized processes, Cerep is happy to expand custom made profiles clients can design at set prices. While offering more flexibility, clients are able to select among predefined lists of functional GPCR, kinase and binding assays. Keywords: In vitro, Pharmacology, Assay, Target, Receptor, Ion channel, Transporter, Enzyme, Mechanism, Hoc, Compound, Kinase, GPCR, Secondary messenger,

Proper citation: CEREP: In Vitro Pharmacology (RRID:SCR_007233) Copy   

•   Source: SciCrunch Registry

http://www.clcbio.com/products/clc-genomics-workbench/

Commercially available software for visualization and analysis of next generation sequencing data. Used for viewing, exploring, and sharing of NGS analysis results. Complete toolkit for genomics, transcriptomics, epigenomics, and metagenomics in one program.

Proper citation: CLC Genomics Workbench (RRID:SCR_011853) Copy   

•   Source: SciCrunch Registry

http://www.scienceexchange.com/facilities/caresbio-laboratory

CaresBio Laboratory (CBL) is a contract research organization, serving as a translational link with the one stop service approach to close the gaps between basic and clinical sciences for biomedical science community. We are serving academic laboratories, CROs, biotechnology and pharmaceutical companies and research organizations by providing high quality and cost effective pre-clinical and clinical research services. If you are doing biomarker and or drug discovery and development; therapeutics and translational research along with the applications of genomics and proteomics study; data validation and analysis; histopathology, immunohistochemistry, pathology or other immunostaining, imaging; histomorphometry, image analysis; small animal imaging; screening, efficacy and toxicity testing of your candidate compounds. We also provide biostatistics analysis of pre-clinical and or clinical data, data base developments or any subcategories of these fields. We do assay developments and provide customized assays to match your needs.

Proper citation: CaresBio Laboratory (RRID:SCR_012393) Copy   

•   Source: SciCrunch Registry

http://cgf.nci.nih.gov

With remarkable advances in genomic technologies, the National Cancer Institute established the Core Genotyping Facility (CGF) to investigate the contribution of germline genetic variation to cancer susceptibility and outcomes. Working in concert with epidemiologists, biostatisticians and basic research scientists in the intramural research program, the CGF has developed the capacity to conduct genome-wide association studies and candidate gene approaches to identify the heritable determinants of various forms of cancer. In order to ensure the accuracy and timely completion of all CGF provided operations, the following Information Systems were developed. While the investigator does not have direct access to these systems, their availability to CGF staff members greatly aids in their querying and reporting capabilities. In turn this provides benefit to the investigator by providing the most up to date reporting possible. The Core Genotyping Facility (CGF) offers a wide variety of sample preparation and genotyping operations. All samples received must meet minimum requirements and are taken through the Sample Handling pipeline prior to completing any genotyping. The Sample Handling pipeline includes DNA quantification and genetic fingerprinting. Also offered are Whole Genome Amplification (WGA) assays, to get the most yield out of low quantity DNA samples. Theirr genotyping products cover a wide-range of assay sizes. The CGF operates the Illumina BeadLab system which supports Illumina assay technologies including the whole genome genotyping Infinium assays, custom GoldenGate OPA assays, and Custom Infinium (iSelect) assays. In addition, the CGF offers Affymetrix GeneChip arrays and uniplex TaqMan genotyping. Sponsors: CGF is supported by the SAIC-Frederick. :Keywords: Genomic, Technology, Cancer, Genotyping, Germline, Genetic, Epidemiologist, Biostatistician, Research, Gene, Assay, Genotype, Pipeline, Genome, DNA, :

Proper citation: Core Genotyping Facility (RRID:SCR_008438) Copy   

•   Source: SciCrunch Registry

http://www.baylor.edu/psychologyneuroscience/

Goal of Department is creation and dissemination of knowledge in psychological sciences, fostering environment conducive to creative scholarship and learning among both students and faculty, and application of knowledge to betterment and service of society. Offers Bachelor of Science and Bachelor of Arts degree in Psychology as well as few undergraduate degree programs in Neuroscience.

Proper citation: Baylor University Department of Psychology and Neuroscience (RRID:SCR_007224) Copy   

•   Source: SciCrunch Registry

http://www.physionet.org/

Collection of dissemination and exchange recorded biomedical signals and open-source software for analyzing them. Provides facilities for cooperative analysis of data and evaluation of proposed new algorithm. Providies free electronic access to PhysioBank data and PhysioToolkit software. Offers service and training via on-line tutorials to assist users at entry and more advanced levels. In cooperation with annual Computing in Cardiology conference, PhysioNet hosts series of challenges, in which researchers and students address unsolved problems of clinical or basic scientific interest using data and software provided by PhysioNet. All data included in PhysioBank, and all software included in PhysioToolkit, are carefully reviewed. Researchers are further invited to contribute data and software for review and possible inclusion in PhysioBank and PhysioToolkit. Please review guidelines before submitting material.

Proper citation: PhysioNet (RRID:SCR_007345) Copy   

•   Source: SciCrunch Registry

http://www.daimi.au.dk/%7Emailund/SNPFile/

Software library and API for manipulating large SNP datasets with associated meta-data, such as marker names, marker locations, individuals'' phenotypes, etc. in an I/O efficient binary file format. In its core, SNPFile assumes very little about the metadata associated with markers and individuals, but leaves this up to application program protocols. (entry from Genetic Analysis Software)

Proper citation: SNPFILE (RRID:SCR_009402) Copy   

•   Source: SciCrunch Registry

http://www.scienceexchange.com/facilities/barts-and-the-london-school-of-medicine-and-dentistry

Barts and The London offers international levels of excellence in research and teaching while serving a population of unrivalled diversity. Through partnership with our linked trusts, notably Barts and The London NHS Trust, and our associated University Hospital Trusts _������������_ Homerton, Newham, Whipps Cross and Queen''''s (Romford) the School''''s research and teaching is informed by an exceptionally wide ranging and stimulating clinical environment.

Proper citation: Barts and The London School of Medicine and Dentistry Labs and Facilities (RRID:SCR_012710) Copy   

•   Source: SciCrunch Registry

http://www.radnet.ucla.edu/sections/DINR/index.htm

Annotated images of human brain derived from CT, MRI, angiography and post-mortem sections and drawings. Brain vasculature: arteries, arterioles, veins. Pathological specimens. Quizzes and general information on brain structures and clinical syndromes. Extensive collection of images, many from pathological conditions.

Proper citation: Salamons Neuroanatomy and Neurovasculature Web-Atlas Resource (RRID:SCR_007343) Copy   

•   Source: SciCrunch Registry

https://www.marshallhealth.org/locations/marshall-neuroscience-huntington

Purpose of Neuroscience department is to treat diseases of central and peripheral nervous systems and their supporting elements including skull and spine, as single system, utilizing expertise of variety of specialists, closely interacting with one another professionally with regard primarily for care of individual patient and their particular situation.Neuroscience department is committed to teaching and research in the fields of neurology and neruosurgery. Residents and medical students are welcome to rotate with us, or to join us for any of our scheduled lectures and conferences.

Proper citation: Marshall University Medical Center Marshall Neuroscience (RRID:SCR_007460) Copy   

•   Source: SciCrunch Registry

https://pharmtox.utoronto.ca/

The Department of Pharmacology is among the oldest and largest in North America, with its official foundations in 1887, at the same time that the Faculty of Medicine was re-established in the University of Toronto. We offer training in pharmacology and toxicology to both undergraduate and graduate students who may subsequently go on to exciting research, regulatory and administrative careers in academic, industrial and healthcare provision settings.Current areas of research investigation in the Department include Receptor Pharmacology, Signal Transduction Pathways, Neuropharmacology, Drug Addiction Studies, Drug Metabolism and Pharmacokinetics, Pharmacogenetics, Cardiovascular Pharmacology, Clinical Pharmacology, Behavioural Pharmacology, Immunopharmacology, Endocrine Pharmacology and Molecular Toxicology. Our research laboratories are located not only in the core Department situated in the Medical Sciences Building on the downtown St. George campus, but also within a number of nearby university Departments, Faculties, university-affiliated research institutes and teaching hospitals. This strategic positioning also enables a wealth of potential opportunities for interdisciplinary collaboration with internationally recognized investigators within one of the largest and densest existing concentrations of biomedical research expertise in North America.

Proper citation: University of Toronto Toronto Ontario Canada Pharmacology and Toxicology (RRID:SCR_007536) Copy   

•   Source: SciCrunch Registry

http://hdbase.org/cgi-bin/welcome.cgi

A community website for Huntington''s Disease (HD) research that currently contains Y2H and Mass spectrometry protein-protein interaction data centered around the HD protein (huntingtin) and information on therapeutic studies in mouse. Also available are raw Human and Mouse Affymetrix Microarray data. The protein interaction data is from several sources, including interactions curated from the literature by ISB staff, experimentally determined interactions produced by Bob Hughes and colleagues at Prolexys (currently password protected), and interactions reported in a recent publication by Goehler et al from Eric Wanker''s lab. Content areas that may be covered by the site include the following: * Therapeutic studies in mouse, primarily drug screens. * HD mouse models with a focus on timelines of disease progression. * Antibodies used in HD research. * Microarray gene expression studies. * Genes and proteins relevant to HD research. This includes HD itself, the growing list of proteins thought to interact directly or indirectly with huntingtin (Htt), and other genes and proteins implicated in the disease process. * Molecular pathways thought to be involved in the disease process. * Timelines of disease for Mouse models

Proper citation: HDBase (RRID:SCR_007132) Copy   

•   Source: SciCrunch Registry

http://cytoseg.googlecode.com

A tool for automatic segmentation of 3D biological datasets, with emphasis on 3D electron microscopy. It works best for 3D blob shaped objects like mitochondria, lysosomes, etc. The project is written in Python and uses the pythonxy platform (which includes scipy and ITK image processing tools).

Proper citation: Cytoseg (RRID:SCR_009553) Copy   

•   Source: SciCrunch Registry